Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: poor quality (76), poor (225), cheap (4)

Papers-CoG 26.04.2023

Description: Agenda attachments 1 CoG Agenda - 26.04.2023.docx Date Time Location Chair Agenda Council of Governors 26/04/2023 14:00 - 16:05 Mic
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-26.04.2023.pdf

About your wig prescription - patient information

Description: If you are diagnosed with a dermatological condition that causes significant hair loss, the Southampton Dermatology Centre will give you a
Url: /Media/UHS-website-2019/Patientinformation/Skin/About-your-wig-prescription-1201-PIL.pdf

Audit and Risk Committee ToR Jan 2023

Description: Audit and Risk Committee Terms of Reference Version: 5 Date Issued: Review Date: Document Type: 31 January 2023 January 2024 Commi
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2023.pdf

Annual complaints report 2020-21

Description: ANNUAL COMPLAINTS REPORT 2020/21 RETROSPECTIVE PERFORMANCE LOOKING FORWARDS “All patients, from every background and walk of life, will experience
Url: /Media/UHS-website-2019/Patientinformation/Contactingus/Annual-complaints-report-2020-21.pdf

RFC PO (Lite) - Cyclophosphamide-Fludarabine- Rituximab PO (Lite) Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE–FLUDARABINE–RITUXIMAB (RFC Oral Lite) Regimen Lymphoma – RFC PO (Lite) - Cyclophosphamide-Fl
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RFC-PO-Lite-Cyclophosphamide-Fludarabine-Rituximab-PO-Lite-Ver-1.2.pdf

BEACOPP escalated

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-ETOPOSIDE-PREDNISOLONEPROCARBAZINE-VINCRISTINE (BEACOPP Esc
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPP-escalated.pdf

BEACOPDac escalated

Description: Chemotherapy Protocol LYMPHOMA BLEOMYCIN-CYCLOPHOSPHAMIDE-DACARBAZINE-DOXORUBICIN-ETOPOSIDEPREDNISOLONE-VINCRISTINE (BEACOPDac Es
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BEACOPDac-escalated.pdf

Audit and Risk Committee ToR Jan 2022

Description: Audit and Risk Committee Terms of Reference Date Issued: 27 January 2022 Review Date: January 2023 Document Type: Committee Terms
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2022.pdf

DVd(Twice weekly)Daratumumab-Bortezomib-Dexamethasone Cycle 9 onwards

Description: Chemotherapy Protocol Myeloma Bortezomib (twice weekly) Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezom
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdTwice-weeklyDaratumumab-Bortezomib-Dexamethasone-Cycle-9-onwards.pdf

Vinorelbine PO (day 1, 8, 15) Ver 1.2

Description: Chemotherapy Protocol BREAST CANCER VINORELBINE Oral (Day 1, 8, 15) Regimen Breast Cancer – Vinorelbine Oral (day 1, 8,
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Vinorelbine-PO-day-1-8-15-Ver-1.2.pdf

121 to 130 of 266

Previous … 11 12 13 14 15 … Next